Table 2.
Disease-associated glycoproteins identified by glycoproteomics
| Protein name | Alternation | Diseases | Reference | Method used |
|---|---|---|---|---|
| Alpha-1-antichymotrypsin (ACT) | Upregulated | Nonsmall cell lung cancer (NSCLC) | [24] | Hydrazide chemistry |
| Alpha-1-antichymotrypsin (ACT) | Upregulated | Hepatocellular carcinoma (HCC) | [81] | Hydrazide chemistry |
| Alpha-1-antitrypsin, 40 kDa variant | Upregulated | HIV | [82] | 2DE analysis |
| Arylsulfatase B | Upregulated | Skin cancer | [25] | Hydrazide chemistry |
| Cathepsin L | Upregulated | Aggressive prostate cancer | [53] | Hydrazide chemistry |
| CEA5 | Upregulated | Mucinous ovarian carcinoma | [54] | Hydrazide chemistry |
| CEA6 | Upregulated | Mucinous ovarian carcinoma | [54] | Hydrazide chemistry |
| CUB domain containing protein 1 | Upregulated | Metastatasic prostate cancer | [47] | Metabolic labeling |
| ER-associated DNAJ (ERdj3) | Upregulated | Paclitaxel-resistant oviarian cancer cells | [83] | Fluorescence-based multiplexed proteomics and multilectin affinity chromatography |
| Fucosylated GP73 | Upregulated | Hepatocellular carcinoma (HCC) | [69] | Lectin |
| Fucosylated Haptoglobin | Upregulated | Lung cancer | [70] | 2DE analysis |
| Galectin-3-binding protein (Gal3BP) (Mac-2 BP, S90K) | Upregulated | Most ovarian cancer subtypes | [54] | Hydrazide chemistry |
| Galectin-3-binding protein (Gal3BP)(Mac-2 BP, S90K) | Upregulated | Hepatocellular carcinoma (HCC) | [31] | Hydrazide chemistry |
| Insulin-like growth factor binding protein 3 (IGFBP-3) | Downregulated | Hepatocellular carcinoma (HCC) | [31] | Hydrazide chemistry |
| Insulin-like growth factor binding protein 3 (IGFBP-3) | Downregulated | Nonsmall cell lung cancer (NSCLC) | [24] | Hydrazide chemistry |
| Mesothelin | Upregulated | High-grade serous, low-grade serous, and transitional-cell ovarian carcinoma | [54] | Hydrazide chemistry |
| Metalloproteinase inhibitor 1 (TIMP1), glycosylated form | Upregulated | Lung cancer | [84] | Lectin |
| Microfibrillar-associated protein 4 | Upregulated | Aggressive prostate cancer | [53] | Hydrazide chemistry |
| Palmitoyl-protein thioesterase 1 (PPT1) | Upregulated | Paclitaxel-resistant ovarian cancer cells | [83] | Fluorescence-based multiplexed proteomics and multilectin affinity chromatography |
| Periostin | Upregulated | Aggressive prostate cancer | [53] | Hydrazide chemistry |
| Periostin | Upregulated | Most ovarian cancer subtypes | [54] | Hydrazide chemistry |
| Prohibitin 1 (PHB) | Upregulated | Liver cancer | [85] | Lectin |
| Prostaglandin D synthase (lipocalin-type) (L-PGDS) | Downregulated | Nonsmall cell lung cancer (NSCLC) | [24] | Hydrazide chemistry |
| Tenascin-C | Upregulated | Skin cancer | [25] | Hydrazide chemistry |
| Thrombospondin 1 (TSP-1) | Downregulated | Hepatocellular carcinoma (HCC) | [31] | Hydrazide chemistry |
| Triose phosphate isomerase (TPI) | Upregulated | Paclitaxel-resistant oviarian cancer cells | [83] | Fluorescence-based multiplexed proteomics and multilectin affinity chromatography |
| Tumor rejection anatigen (gp96) | Upregulated | Paclitaxel resistant oviarian cancer cells | [83] | Fluorescence-based multiplexed proteomics and multilectin affinity chromatography |
| Versican | Upregulated | Breast cancer | [28] | Hydrazide chemistry |
| Versican | Upregulated | Most ovarian cancer subtypes | [54] | Hydrazide chemistry |